Head-to-head · WeighScore
Bayan Health vs Somi Health
The verdict
Bayan Health takes it — 74.6/100 to 68.7/100.
Bayan Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Bayan Health sells a flat-dose GLP-1 protocol at $129 and $149 and binds you to the whole protocol in the same paragraph that offers a monthly bill.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Bayan Health | Somi Health |
|---|---|---|
| WeighScore | 74.6/100 | 68.7/100 |
| Grade | C | C |
| Site position | #65 | #159 |
| Semaglutide | $129/mo (billed monthly against a protocol that ships three months at a time) | $135/mo (starting dose, compounded) |
| Tirzepatide | $149/mo (billed monthly against a protocol that ships three months at a time) | $165/mo (starting dose, compounded) |
| Coverage | All 50 states (claimed; no list published) | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Site position #65 · C
Strengths
- Both product pages state the price holds at every dose, so the figure does not climb as titration does
- Sells oral drops and microdose tiers below the standard injectable rate, and prices oral orforglipron tablets openly at $269 a month
- Names its clinical network, MD Integrations, and its founding physician
- Publishes an itemized fee table for consultations, follow-ups and quarterly clinical reviews rather than leaving them unpriced
- Ships free, and the medication cost is stated as included in the monthly figure
Where it loses points
- The monthly bill is not a monthly commitment: the Terms require opting out at least fifteen days before the next protocol cycle, and the payment obligation covers the whole two- to three-month protocol shipped
- The refund policy opens “ALL SALES ARE FINAL” and consultations are non-refundable
- The homepage says medication pricing depends on a personalized treatment plan while the product pages say the price is flat at every dose
- The FAQ says service is available nationwide, the Terms say it may not be available in all states, and no list is published
- No pharmacy is named — the site states only that it uses licensed 503A and 503B pharmacies
- No legal entity, entity suffix or street address is published anywhere on the site
- The transparent-pricing table still contains an unedited placeholder row reading “Service name $20”
Site position #159 · C
Strengths
- Among the lowest compounded prices: semaglutide $135/mo, tirzepatide $165/mo (3-month plan)
- Oral semaglutide tablet option for those who want no injections
- One price at any dose, with the medical visit and shipping included
- LegitScript Approved seal displayed; partnered with 503A pharmacies
- Free 2-5 day shipping; no insurance required
Where it loses points
- Compounded only - no brand-name Wegovy, Zepbound, Ozempic or Mounjaro
- Homepage advertises a 100% money-back guarantee but Terms state all sales are final, no refunds on medication
- Partner pharmacies are not individually named (material transparency gap)
- No single prescribing medical group named; only affiliated professional entities
- State availability not published; confirmed only during intake
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). CoreAge Rx advertises flat dose pricing for compounded injections, with no membership fee; its consultation-fee and refund deadlines deserve a close read before paying.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.